Irinotecan, TAS-102 Plus Bevacizumab as a Second-Line Therapy in mCRC Patients
Clinical trial NCT06202001 · RECRUITING
Trial details
- NCT number
- NCT06202001
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-10-01
- Primary completion
- 2025-09-30
- Enrollment
- 70
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.